Clincosm LogoSign in Get a demo

enzyme inhibitors

Showing 1 - 6 of 6
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC, NSCLC, Carcinoma, Bronchogenic Trial in Worldwide (Furmonertinib)

Recruiting
  • Non-Small Cell Lung Cancer
  • +14 more
  • Glendale, California
  • +12 more
Feb 2, 2023

Prostatic Tumors, Tumor Metastasis, Urogenital Tumors Trial in Worldwide (Abemaciclib, Abiraterone, Prednisone or Prednisolone)

Recruiting
  • Prostatic Neoplasms
  • +16 more
  • Birmingham, Alabama
  • +296 more
Jan 18, 2023

Carcinoma, Carcinoma, Renal Cell, Kidney Tumors Trial in Worldwide (Savolitinib, Sunitinib)

Active, not recruiting
Has Results
  • Carcinoma
  • +7 more
  • La Jolla, California
  • +58 more
Jan 13, 2023

NSCLC, NSCLC, Carcinoma, Bronchogenic Trial in United States (furmonertinib 240 mg, furmonertinib 160 mg, platinum-based chemo)

Recruiting
  • Non-Small Cell Lung Cancer
  • +13 more
  • furmonertinib 240 mg
  • +2 more
  • Yuma, Arizona
  • +37 more
Dec 14, 2022

Hydroxychloroquine, Antimalarials, Enzyme Inhibitors Trial in Mexico City (Hydroxychloroquine Sulfate, Bromhexine 8 MG)

Enrolling by invitation
  • Hydroxychloroquine
  • +3 more
  • Hydroxychloroquine Sulfate
  • Bromhexine 8 MG
  • Mexico City, Cdmx, Mexico
    National Institute of Rehabilitation, Luis Guillermo Ibarra Ibar
Jun 26, 2021

Ovarian Tumors, Fallopian Tube Tumors, Endocrine Gland Tumors Trial in Nanjing (Niraparib, Bevacizumab)

Unknown status
  • Ovarian Neoplasms
  • +23 more
  • Nanjing, Jiangsu, China
    JiangSu Cancer Hospital
Nov 8, 2020